Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/23/2013 |
| Start Date: | February 2011 |
| End Date: | December 2013 |
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
The purpose of this study is to determine if AB0024 is effective in treating patients with
Primary Myelofibrosis, and Post-Polycythemia Vera or Post-Essential Thrombocythemia
Myelofibrosis.
Inclusion Criteria:
- Diagnosed with Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential
Thrombocythemia Myelofibrosis
- Adequate organ function
- ECOG performance ≤ 2
Exclusion Criteria:
- Known history of human immunodeficiency virus, hepatitis C, or hepatitis B
- Use of any growth factors, cytotoxic chemotherapeutic agents, corticosteroids, or
immunomodulators within 2 weeks and interferon use within 4 weeks prior to study Day
1.
- History of surgery within 2 weeks prior to enrollment
We found this trial at
2
sites
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Stanford University Cancer Institute The Stanford Cancer Institute (SCI) focuses the world-class expertise of more...
Click here to add this to my saved trials